2003
DOI: 10.1159/000074078
|View full text |Cite
|
Sign up to set email alerts
|

A Method for Estimating Duration of Illness in Alzheimer’s Disease

Abstract: Background: We developed a set of questions for generating an estimate regarding the date of first symptoms to the nearest half-year. Physicians then revised this estimate in conjunction with medical record review and patient/informant interviews, and by testing the estimate by recall of life events. One experienced examiner rated 36 patients, and each was independently rated by a second, less experienced rater. The physician ratings were compared to each other and to an unstructured caregiver estimate of dura… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
22
0
1

Year Published

2004
2004
2021
2021

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 40 publications
(23 citation statements)
references
References 7 publications
0
22
0
1
Order By: Relevance
“…With this technique a single variable has been extracted from all CERAD subscale variables reflecting most of the variance observed in the CERAD subscale variables. The following variables were used as independent variables: PrP C concentration in the patients' CSF, age, pre-progression time (PPT) (estimated time from first clinical manifestation of the disease until establishment of the diagnosis 34 ), gender, use of nicotine, presence of diabetes mellitus, use of benzodiazepines, use of antidepressants, use of neuroleptic drugs, use of anti-dementia drugs, prion protein gene (PRNP) genotype, ApoE genotype and level of education (years of formal/ institutional education). injury and cell death have been proposed.…”
Section: Methodsmentioning
confidence: 99%
“…With this technique a single variable has been extracted from all CERAD subscale variables reflecting most of the variance observed in the CERAD subscale variables. The following variables were used as independent variables: PrP C concentration in the patients' CSF, age, pre-progression time (PPT) (estimated time from first clinical manifestation of the disease until establishment of the diagnosis 34 ), gender, use of nicotine, presence of diabetes mellitus, use of benzodiazepines, use of antidepressants, use of neuroleptic drugs, use of anti-dementia drugs, prion protein gene (PRNP) genotype, ApoE genotype and level of education (years of formal/ institutional education). injury and cell death have been proposed.…”
Section: Methodsmentioning
confidence: 99%
“…Age at onset was estimated to the nearest half year by the clinician, using standardized methodology [17]. Briefly, this method included an interview with the patient and all available informants, review of medical records to look for previous chronologies, and asking the patient’s caregiver to estimate the duration of 34 symptoms commonly associated with AD.…”
Section: Methodsmentioning
confidence: 99%
“…AAO was determined with two standardized methods in the TARC cohort according to previously published data [18, 19]: i) caregiver estimate of onset of symptoms and ii) physician estimate of duration of illness using a structured interview with landmark event to facilitate recall [20]. AAO in the LOAD cohort was determined by a standard question inquiring when the symptoms started.…”
Section: Methodsmentioning
confidence: 99%